236 related articles for article (PubMed ID: 21911695)
1. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.
Roe CM; Fagan AM; Grant EA; Marcus DS; Benzinger TL; Mintun MA; Holtzman DM; Morris JC
Arch Neurol; 2011 Sep; 68(9):1145-51. PubMed ID: 21911695
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
4. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
5. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
8. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
[TBL] [Abstract][Full Text] [Related]
9. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC
JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A
Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
14. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.
Roe CM; Fagan AM; Grant EA; Hassenstab J; Moulder KL; Maue Dreyfus D; Sutphen CL; Benzinger TL; Mintun MA; Holtzman DM; Morris JC
Neurology; 2013 May; 80(19):1784-91. PubMed ID: 23576620
[TBL] [Abstract][Full Text] [Related]
15. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
Tosun D; Schuff N; Truran-Sacrey D; Shaw LM; Trojanowski JQ; Aisen P; Peterson R; Weiner MW;
Neurobiol Aging; 2010 Aug; 31(8):1340-54. PubMed ID: 20570401
[TBL] [Abstract][Full Text] [Related]
16. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease.
Roe CM; Fagan AM; Williams MM; Ghoshal N; Aeschleman M; Grant EA; Marcus DS; Mintun MA; Holtzman DM; Morris JC
Neurology; 2011 Feb; 76(6):501-10. PubMed ID: 21228296
[TBL] [Abstract][Full Text] [Related]
17. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
20. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
